Josh Phillipson 11/3/23 Josh Phillipson 11/3/23

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

Read More

Josh Phillipson 10/31/23 Josh Phillipson 10/31/23

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot

Read More

Josh Phillipson 10/31/23 Josh Phillipson 10/31/23

Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update

Read More

Josh Phillipson 10/30/23 Josh Phillipson 10/30/23

Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023

Read More

Josh Phillipson 10/4/23 Josh Phillipson 10/4/23

Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023

Read More

Josh Phillipson 9/19/23 Josh Phillipson 9/19/23

Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

Read More

Josh Phillipson 9/15/23 Josh Phillipson 9/15/23

Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

Read More

Josh Phillipson 9/13/23 Josh Phillipson 9/13/23

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Read More

Josh Phillipson 9/11/23 Josh Phillipson 9/11/23

Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston

Read More

Josh Phillipson 9/6/23 Josh Phillipson 9/6/23

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Scinai Immunotherapeutics

Read More

Guest User 8/11/23 Guest User 8/11/23

BiondVax Reports Second Quarter Financial Results and Provides Business Update

Read More

Guest User 8/1/23 Guest User 8/1/23

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Read More

Guest User 6/5/23 Guest User 6/5/23

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Read More

Guest User 5/15/23 Guest User 5/15/23

BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update

Read More

Guest User 4/17/23 Guest User 4/17/23

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Read More

Guest User 3/16/23 Guest User 3/16/23

BiondVax to Present at BIO-Europe Spring

Read More

Guest User 2/2/23 Guest User 2/2/23

BiondVax Presenting at BIO CEO & Investor Conference

Read More

Guest User 1/23/23 Guest User 1/23/23

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

Read More

Guest User 1/6/23 Guest User 1/6/23

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

Read More

Guest User 1/5/23 Guest User 1/5/23

BiondVax to Present at Biotech Showcase 2023

Read More